

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/141121 A1

(43) International Publication Date
15 July 2021 (15.07.2021)

(51) International Patent Classification:

C12N 15/117 (2010.01) A61P 37/00 (2006.01)
A61K 31/711 (2006.01)

(21) International Application Number:

PCT/JP2021/000543

(22) International Filing Date:

08 January 2021 (08.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2020-002715 10 January 2020 (10.01.2020) JP

(71) Applicant: **SBI BIOTECH CO., LTD.** [JP/JP]; 1-6-1,
Roppongi, Minato-ku, Tokyo, 1066015 (JP).

(72) Inventor: **ESASHI Eiji**; c/o SBI BIOTECH CO., LTD.,
1-6-1, Roppongi, Minato-ku, Tokyo, 1066015 (JP).

(74) Agent: **TSUKUNI & ASSOCIATES** et al.; Kojimachi
Business Center, 5-3-1, Kojimachi, Chiyoda-ku, Tokyo,
1020083 (JP).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: NOVEL TLR9 AGONISTS

(57) Abstract: The present application provides novel oligonucleotides and therapeutic use thereof. The oligonucleotides of the present invention can be used for the activation or modulation of immunity in the subject.

